56 results
8-K
EX-10.1
FENC
Fennec Pharmaceuticals Inc
21 Mar 24
Fennec Pharmaceuticals and Norgine Enter into Exclusive Licensing Agreement to Commercialize PEDMARQSI in Europe, Australia, and New Zealand
4:02pm
times. Licensee shall immediately notify Fennec of any adverse reaction, side effect, injury, toxicity or sensitivity reaction, whether … injury or death, to the extent such Third Party Claims arise from the period of time commencing on or after the Effective Date and to the extent
8-K
EX-99.1
FENC
Fennec Pharmaceuticals Inc
2 Feb 24
FDA Issues Reminder of Non-Substitution of PEDMARKÒ (sodium thiosulfate injection) for Pediatric Patients Receiving Cisplatin
12:00am
in PEDMARK.
Overexposure to boric acid (a boron compound), can cause health risks including headache, hypothermia, restlessness, weariness, renal injury
424B5
o4ijg qszl3
1 May 20
Prospectus supplement for primary offering
5:28pm
424B5
w1q9wot2j0yn nkirop9
29 Apr 20
Prospectus supplement for primary offering
4:48pm
424B3
0j3hyddpji5tz2eyo pv
21 Apr 14
Prospectus supplement
12:00am
8-K
EX-10.23
wtuwi6
20 Jun 13
Departure of Directors or Certain Officers
12:00am
424B3
6fcj5rxlxt4svajj1
4 Apr 13
Prospectus supplement
12:00am
POS AM
k1mtk hvup7fr
1 Apr 13
Prospectus update (post-effective amendment)
12:00am